$RKLB — HOLD | 6 MONTHS THESIS

Revenue: $236M

Expectations gap: Consensus/market is pricing a successful, on-time-ish Neutron and a clean Iridium close. The gap is in timing, not direction: (1) Stale consensus Q3 revenue of ~$236M sits BELOW management's $250-265M guide, so a revenue beat-and-raise is plausible and partly expected — it is unlikely to be the source of a surprise. (2) The market appears to still credit some probability of a 2026 Neutron launch; realistic base case is pad delivery in Q4 2026 with first flight in 2027, i.e., headline risk skewed to the downside on schedule. (3) Dilution is under-modeled in casual coverage: 29.3M shares already issued at ~$66 average (~5% dilution) plus 25-42M more at close from the 0.24-0.40 exchange ratio — up to ~12% total share count growth — plus Rocket Lab guaranteeing Iridium's $1.775B term loan. (4) Conversely, the market may under-price the speed of the profitability inflection: Iridium adds ~$872-884M of revenue at ~57-72% gross/OEBITDA margin and, by sell-side estimates, >$135M GAAP profit and >$313M FCF in 2027 — enough to flip the combined company cash-flow positive a year earlier than previously modeled. That is a mid-2027 event, not a 6-month one.

Business quality: 7/10

Valuation: Market cap ~$41.8B on ~598M shares (plus ~41M preferred converting 1:1) at $73.61. Against 2026E revenue of ~$1.0-1.1B that is ~38-42x sales; EV is higher once Iridium's $1.775B term loan is included at close. Even on a 2027 pro-forma combined revenue base of roughly $1.8B, that is ~23x sales for a low-30s-gross-margin, historically net-loss business — versus ~2x sales for legacy primes (LMT/RTX, low-single-digit growers) and roughly 8-15x for pure-play space peers. There is no near-term earnings anchor: Q3 consensus EPS is -$0.0673 (~-$40M net loss) and Q2 net loss was $49.3M. Valuation therefore rests entirely on 2030+ Neutron launch cadence and constellation economics, discounted at a rising risk-free rate (10-yr at 5.19%). Sell-side consensus targets cluster ~$108-115 (Cantor $122 max bull, ClearRank/Sell low end at fair value ~$64), so the Street sees 45-65% upside — but those targets are built on the same out-year assumptions, not on anything verifiable in the next two quarters. Not 'cheap' by any measurable metric; 'reasonable only if you underwrite Neutron plus Iridium together and accept a 2027+ payoff.'

Reference class: Pre-profit, high-beta space/defense hard-tech prime with a single binary development program (Neutron) and a transformational acquisition in regulatory limbo (Iridium). Beta ~2.61; 89 single-day moves greater than 5% over the trailing year. Best comps: pre-scale launch/space names (AST SpaceMobile, Firefly, Intuitive Machines) for multiple behavior, and primes (LMT, RTX, NOC) for end-market demand. Trade it as a high-multiple growth/event stock, not as an Industrials value name — the Russell 1000 / Industrials sector label is misleading.

Catalyst: Q3 FY26 earnings (Nov 9, 2026) followed by Q4/FY26 results (~late Feb 2027), with Neutron 'delivery to the pad in Q4 2026' milestone headlines and Iridium closing-path developments (shareholder vote was Sept 24; close targeted mid-2027) interspersed.

Sizing: Zero core weight at Hold — this is a watchlist name. If a discretionary position must be carried, cap it at 0.5-1.0% of portfolio NAV (roughly one-third to one-half of a normal 2-3% single-name allocation) because a 2.6-beta, event-driven print can gap 15-25% either way. Do not carry a naked short at this size or larger: borrow cost is real and squeeze risk is acute in a name with an active retail/ARK bid. Any long taken on a confirmed Neutron milestone should be sized to survive a full retrace to $58-62.

Invalidation: Neutral stance is invalidated toward LONG by: Neutron confirmed on the pad at Wallachia/Wallops with a completed static fire and a public launch date, combined with a Q3 revenue beat above $265M at GAAP GM >=31% and no further equity issuance. Neutral stance is invalidated toward SHORT by: Q3 revenue below $250M or GAAP GM below 29%, a Neutron pad milestone slipping out of Q4 2026, any new ATM/equity raise, or Iridium close delayed past mid-2027. Technically, a decisive break below ~$58-60 (post-September consolidation floor) or a sustained move above ~$85 (upper end of the post-ATM recovery range) each resolves the range and would justify a directional position.

Hold / watchlist only. RKLB is a high-quality, best-in-class space platform with 62% YoY revenue growth and a record $2.36B backlog, but at $73.61 the stock trades at roughly 38-42x 2026E sales for a company still guiding to a $17-23M quarterly EBITDA loss and ~30% GAAP gross margin. The two events that would justify the multiple — an Iridium close (mid-2027) and a Neutron first launch (likely 2027, already slipped five times) — fall outside the 6-month horizon, leaving only the Nov 9 Q3 print and Neutron pad headlines as near-term drivers, which are roughly symmetric risks. With the stock up ~19% in two weeks into that print, the 10-year at 5.19%, and up to ~12% total dilution plus a $1.775B debt guarantee incoming, the near-term reward/risk is balanced rather than compelling. Levels are withheld because no directional edge exists at this price; the actionable plan is to wait, then go long on a confirmed Q3 beat plus dated Neutron pad milestone above ~$80, or short a guidance miss / renewed dilution below ~$62. Note the weak-company/great-stock asymmetry in reverse: this is a strong company whose stock is priced for perfect execution.